OTCMKTS:TRPXD

Therapix Biosciences Competitors

$5.98

-3.10 (-34.14 %)

(As of 11/11/2020)

Add

Compare

Today's Range

$5.50

Now: $5.98▼

$5.98

50-Day Range

$5.98

MA: $7.59▼

$9.19

52-Week Range

$2.75

Now: $5.98▼

$22.40

Volume900 shs

Average Volume1,852 shs

Market Capitalization$299,000.00

P/E RatioN/A

Dividend YieldN/A

BetaN/A

Therapix Biosciences (OTCMKTS:TRPXD) Vs. WWHC, IMUC, CDXI, ETST, MLNTQ, and AKAOQ

Should you be buying TRPXD stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Therapix Biosciences, including W World (WWHC), ImmunoCellular Therapeutics (IMUC), Cardax (CDXI), Earth Science Tech (ETST), Melinta Therapeutics (MLNTQ), and Achaogen (AKAOQ).

Therapix Biosciences vs. W World Stock

W World (OTCMKTS:WWHC) and Therapix Biosciences (OTCMKTS:TRPXD) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, institutional ownership, risk, dividends, valuation and earnings.

Valuation & Earnings

This table compares W World and Therapix Biosciences' revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
W World	N/A	N/A	N/A	N/A	N/A
Therapix Biosciences	N/A	N/A	$-4,790,000.00	N/A	N/A

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for W World and Therapix Biosciences, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
W World	0	0	0	0	N/A
Therapix Biosciences	0	0	0	0	N/A

Profitability

This table compares W World and Therapix Biosciences' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
W World	N/A	N/A	N/A
Therapix Biosciences	N/A	N/A	N/A

Institutional and Insider Ownership

0.1% of W World shares are held by institutional investors. Comparatively, 14.3% of Therapix Biosciences shares are held by institutional investors. 61.1% of W World shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Therapix Biosciences vs. ImmunoCellular Therapeutics Stock

Therapix Biosciences (OTCMKTS:TRPXD) and ImmunoCellular Therapeutics (OTCMKTS:IMUC) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, earnings, institutional ownership, dividends, valuation and risk.

Valuation and Earnings

This table compares Therapix Biosciences and ImmunoCellular Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Therapix Biosciences	N/A	N/A	$-4,790,000.00	N/A	N/A
ImmunoCellular Therapeutics	N/A	N/A	N/A	N/A	N/A

Analyst Recommendations

This is a summary of recent recommendations for Therapix Biosciences and ImmunoCellular Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Therapix Biosciences	0	0	0	0	N/A
ImmunoCellular Therapeutics	0	0	0	0	N/A

Profitability

This table compares Therapix Biosciences and ImmunoCellular Therapeutics' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Therapix Biosciences	N/A	N/A	N/A
ImmunoCellular Therapeutics	N/A	N/A	N/A

Institutional and Insider Ownership

14.3% of Therapix Biosciences shares are held by institutional investors. 3.3% of ImmunoCellular Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Therapix Biosciences vs. Cardax Stock

Therapix Biosciences (OTCMKTS:TRPXD) and Cardax (OTCMKTS:CDXI) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, earnings, institutional ownership, dividends, valuation and risk.

Profitability

This table compares Therapix Biosciences and Cardax's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Therapix Biosciences	N/A	N/A	N/A
Cardax	-891.77%	N/A	-297.64%

Analyst Recommendations

This is a summary of recent recommendations for Therapix Biosciences and Cardax, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Therapix Biosciences	0	0	0	0	N/A
Cardax	0	0	0	0	N/A

Institutional and Insider Ownership

14.3% of Therapix Biosciences shares are held by institutional investors. Comparatively, 8.7% of Cardax shares are held by institutional investors. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Valuation and Earnings

This table compares Therapix Biosciences and Cardax's top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Therapix Biosciences	N/A	N/A	$-4,790,000.00	N/A	N/A
Cardax	$710,000.00	2.35	$-5,090,000.00	N/A	N/A

Therapix Biosciences has higher earnings, but lower revenue than Cardax.

Summary

Therapix Biosciences beats Cardax on 4 of the 5 factors compared between the two stocks.

Therapix Biosciences vs. Earth Science Tech Stock

Earth Science Tech (OTCMKTS:ETST) and Therapix Biosciences (OTCMKTS:TRPXD) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, valuation, analyst recommendations, earnings, institutional ownership, risk and dividends.

Profitability

This table compares Earth Science Tech and Therapix Biosciences' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Earth Science Tech	-1,750.31%	N/A	-2,929.76%
Therapix Biosciences	N/A	N/A	N/A

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Earth Science Tech and Therapix Biosciences, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Earth Science Tech	0	0	0	0	N/A
Therapix Biosciences	0	0	0	0	N/A

Institutional & Insider Ownership

14.3% of Therapix Biosciences shares are owned by institutional investors. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares Earth Science Tech and Therapix Biosciences' top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Earth Science Tech	$530,000.00	3.14	$-1,200,000.00	N/A	N/A
Therapix Biosciences	N/A	N/A	$-4,790,000.00	N/A	N/A

Earth Science Tech has higher revenue and earnings than Therapix Biosciences.

Summary

Therapix Biosciences beats Earth Science Tech on 3 of the 5 factors compared between the two stocks.

Therapix Biosciences vs. Melinta Therapeutics Stock

Melinta Therapeutics (OTCMKTS:MLNTQ) and Therapix Biosciences (OTCMKTS:TRPXD) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, analyst recommendations, institutional ownership, earnings, valuation, dividends and profitability.

Profitability

This table compares Melinta Therapeutics and Therapix Biosciences' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Melinta Therapeutics	N/A	N/A	N/A
Therapix Biosciences	N/A	N/A	N/A

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Melinta Therapeutics and Therapix Biosciences, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Melinta Therapeutics	0	0	0	0	N/A
Therapix Biosciences	0	0	0	0	N/A

Earnings and Valuation

This table compares Melinta Therapeutics and Therapix Biosciences' top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Melinta Therapeutics	$96.43 million	0.02	$-157,190,000.00	N/A	N/A
Therapix Biosciences	N/A	N/A	$-4,790,000.00	N/A	N/A

Therapix Biosciences has lower revenue, but higher earnings than Melinta Therapeutics.

Institutional and Insider Ownership

14.3% of Therapix Biosciences shares are owned by institutional investors. 60.3% of Melinta Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Therapix Biosciences vs. Achaogen Stock

Therapix Biosciences (OTCMKTS:TRPXD) and Achaogen (OTCMKTS:AKAOQ) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, valuation, institutional ownership, risk, profitability, analyst recommendations and dividends.

Profitability

This table compares Therapix Biosciences and Achaogen's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Therapix Biosciences	N/A	N/A	N/A
Achaogen	N/A	N/A	N/A

Analyst Recommendations

This is a summary of current ratings and price targets for Therapix Biosciences and Achaogen, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Therapix Biosciences	0	0	0	0	N/A
Achaogen	0	0	0	0	N/A

Valuation & Earnings

This table compares Therapix Biosciences and Achaogen's gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Therapix Biosciences	N/A	N/A	$-4,790,000.00	N/A	N/A
Achaogen	$8.73 million	0.14	$-186,510,000.00	N/A	N/A

Therapix Biosciences has higher earnings, but lower revenue than Achaogen.

Institutional and Insider Ownership

14.3% of Therapix Biosciences shares are owned by institutional investors. Comparatively, 0.0% of Achaogen shares are owned by institutional investors. 7.8% of Achaogen shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.